Under the Medicare Drug Price Negotiation Program, the HHS secretary negotiates directly with manufacturers on the prices Medicare will pay for pharmaceuticals.

The Centers for Medicare & Medicaid Services May 12 released draft guidance for the third round of negotiations for the Medicare Drug Price Negotiation Program. The guidance includes policies incorporating drugs payable under Medicare Part B into the program for the first time and is soliciting comments on how to facilitate access to any negotiated maximum fair price for Part B drugs.

The Trump administration is already gearing up for another round of Medicare drug price negotiations, while OpenAI launched a new evaluation tool.

In signing an executive order aimed at reducing U.S. drug prices, President Donald Trump said some prices would be cut in half or more "almost immediately." But the order is light on details of how the plan would be implemented.

President Trump on Monday called on drugmakers to lower their prices within the next month to be closer to those charged in other high-income countries, threatening to subject them to steep caps on how much they can earn from Medicare if they fail to do so.

The executive order directs Trump's administration to take actions against "discriminatory" policies in foreign countries that suppress drug prices.

CMS draft expands drug price talks to include Medicare Part B drugs and outlines steps for future renegotiations; public comments due by June 26.

Delaying Medicare’s ability to negotiate prices on small-molecule drugs until 13 years after FDA approval will decrease the amount of Medicare spending subject to price negotiation by billions of dollars annually.

It’s unclear what — if any — impact the Republican president’s executive order will have on millions of Americans who have private health insurance.

When Congress adopted the Inflation Reduction Act (IRA) in 2022, creating the Medicare Drug Price Negotiation Program (MDPNP), the bill did

Lecanemab binds with high affinity to soluble amyloid-beta protofibrils. It won full FDA approval in July 2023 based on trial data showing that it slowed cognitive decline in people with early symptomatic Alzheimer's disease, defined as mild cognitive impairment, very mild dementia, or mild dementia due to Alzheimer's.

As he launches a North American stadium tour and his "Hurry Up Tomorrow" film, Abel Tesfaye reflects on losing his voice onstage in 2022 and his decision to stop using his longtime stage name of The Weeknd. (May 7) The days of unlimited Medicare prescription drug costs are finally over.